By: G. Verhoef MD, PhD, W. Schroyens MD, PhD, D. Bron MD, PhD, C. Bonnet MD, PhD, V. De Wilde MD, PhD, A. Van Hoof MD, PhD, A. Janssens MD, PhD, D. Dierickx MD, PhD, M. André MD, PhD, E. Van den Neste MD, PhD
The guidelines for adult patients in this article are based on 2011 ESMO and NCCN version 4.2011 guidelines and amended for the particular Belgian context of label prescription and reimbursement. Levels of evidence for the use of treatment recommendations are given in square brackets. Statements without grading were considered justifed standard clinical practice by the experts of the BHS-lymphoma working party.
(BELG J HEMATOL 2013;4(2):51–57)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
